David E. Goel
At a glance: David E. Goel is 10% Owner at Zentalis Pharmaceuticals (ZNTL). Their latest SEC Form 4, filed Dec 15, 2025, reported a sale of $10.0M. On file: 0 purchase lines ($0) and 1 sale line ($10.0M).
Disclosed holdings: about $8.5M of ZNTL stock: 6,459,973 shares (including shares held indirectly, e.g. through a trust or fund) reported on their latest Form 4 (filed Dec 15, 2025), valued at the Nov 19, 2026 close of $1.31. This counts only ZNTL shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
10% Owner at Zentalis Pharmaceuticals, Inc. (ZNTL)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
David E. Goel's InsiderPrint
2 trades from SEC Form 4 filings, 2021 to 2025, drawn as one fingerprint.
- Bump outward: a purchase (1)
- Dent inward: a sale (1)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Dec 15SEC | ZNTLZentalis Pharmaceuticals, Inc. | Sell | 7,500,0006,459,973 held (−54%) | $1.33 | $10.0M | -1.5% |
- Sell
10% Owner David E. Goel sold $10.0M of ZNTL at $1.33 — cuts the stake by 54%.
Follow David E. Goel
Get one email when David E. Goel files a new purchase or sale. Free.
At most one email a day about David E. Goel, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.